KLHL17 Inhibitors

KLHL17 inhibitors encompass a class of compounds that aim to modulate the activity or function of the KLHL17 protein. While direct inhibitors of KLHL17 remain unidentified, this class incorporates various agents that influence pathways associated with KLHL17, particularly those related to protein synthesis and degradation. Cycloheximide and Rapamycin, for instance, target eukaryotic protein synthesis, offering a strategic avenue for the indirect modulation of KLHL17, given its reported role in synaptic protein regulation. The ubiquitin-proteasome system, pivotal in protein degradation, is targeted by MG-132, which could indirectly affect KLHL17's functional role in this context. Compounds like Chloroquine and Bafilomycin A1, on the other hand, focus on lysosomal protein degradation, offering another indirect approach to influence KLHL17. The PI3K/Akt/mTOR signaling axis, crucial in controlling protein synthesis and degradation, is targeted by agents like LY294002, Wortmannin, and Akt Inhibitor IV. This pathway's modulation can impact the broader protein regulatory milieu wherein KLHL17 operates. Lastly, by targeting proteases (Leupeptin, E-64) and cellular stress pathways (SP600125), we harness another strategic dimension to influence the cellular environment of KLHL17, thus modulating its activity or expression indirectly.